1-3 of 3
J. Lin, PhD
Close
Sort by
Journal Articles

Combination Of Ibrutinib With ABT-199, a BCL-2 Pathway Inhibitor: Effective Therapeutic Strategy In a Novel Mantle Cell Lymphoma Cell Line Model

Xiaoxian Zhao, PhD, Juraj Bodo, PhD, Danyu Sun, MD, PhD, Jeffrey J. Lin, PhD, Lisa Durkin, Shashirekha Shetty, PhD, Mitchell R. Smith, MD, PhD, Eric D. Hsi, MD
Journal: Blood
Blood (2013) 122 (21): 645.
https://doi.org/10.1182/blood.V122.21.645.645
Published: 2013
Journal Articles

Molecular Subtype Characterization of Formalin-Fixed, Paraffin-Embedded Diffuse Large B-Cell Lymphoma Samples on the Iceplex® System.

Angela M. B. Collie, MD, PhD, Jork Nolling, PhD, Jeffrey J. Lin, PhD, Brian T. Hill, MD, PhD, Tomas Radivoyevitch, PhD, Lilly Kong, DVM, Eric D. Hsi, MD
Journal: Blood
Blood (2012) 120 (21): 2705.
https://doi.org/10.1182/blood.V120.21.2705.2705
Published: 2012
Journal Articles

Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).

David S. Siegel, MD, PhD, A. Krishnan, MD, S. Lonial, MD, G. Chatta, MD, M. Alsina, MD, S. Jagannath, MD, P. Richardson, MD, R.J. Hohl, MD, J.A. Lust, MD, W. Bensinger, MD, G. Carrum, MD, J. Moreb, MD, A. Simic, MD, B. Barlogie, MD.PhD, R.T. Maziarz, MD, K.C. Anderson, MD, J. Lin, PhD, A. Lowe, MD, S. Vetticaden, MD, PhD, J. Zhu, MD
Journal: Blood
Blood (2006) 108 (11): 3580.
https://doi.org/10.1182/blood.V108.11.3580.3580
Published: 2006